Dual-target inhibitors of indoleamine 2, 3 dioxygenase 1 (Ido1): A promising direction in cancer immunotherapy

• Published in: European journal of medicinal chemistry Vol. 238; p. 114524
• Main Authors: Zhang, Ya, Hu, Zelin, Zhang, Jifa, Ren, Changyu, Wang, Yuxi
• Format: Journal Article
• Language: English
• Published: France Elsevier Masson SAS 05.08.2022
• Subjects: Cancer immunotherapy; Dual target inhibitor; IDO1; TDO; Cancer immunotherapy; Dual target inhibitor; TDO; IDO1

Indoleamine 2, 3-dioxygenase 1 (IDO1) is a rate-limiting enzyme that catalyzes the kynurenine (Kyn) pathway of tryptophan metabolism in the first step, and the kynurenine pathway plays a fundamental role in immunosuppression in the tumor microenvironment. Therefore, researchers are vigorously develo...